Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Trends Pharmacol Sci. 2012 Oct;33(10):559-64. doi: 10.1016/j.tips.2012.05.005. Epub 2012 Jun 23.
Prostacyclin (PGI(2)) is a potent vasodilator that exerts multiple vasoprotective effects in the cardiovascular system. The effects of PGI(2) are mediated by activation of the cell membrane G-protein-coupled PGI(2) receptor (IP receptor). More recently, however, it has been suggested that PGI(2) might also serve as an endogenous ligand and activator of nuclear peroxisome proliferator-activated receptorδ (PPARδ). Consistent with this concept, studies designed to define pharmacological properties of stable PGI(2) analogs revealed that beneficial effects of these compounds appear to be mediated, in part, by activation of PPARδ. This review discusses emerging evidence regarding the contribution of PPARδ activation to vasoprotective and regenerative functions of PGI(2) and stable analogs of PGI(2).
前列环素(PGI₂)是一种强效的血管扩张剂,在心血管系统中发挥多种血管保护作用。PGI₂的作用是通过激活细胞膜 G 蛋白偶联的 PGI₂受体(IP 受体)来介导的。然而,最近有人提出,PGI₂也可能作为核过氧化物酶体增殖物激活受体δ(PPARδ)的内源性配体和激活剂。与这一概念一致的是,旨在确定稳定的 PGI₂类似物的药理学特性的研究表明,这些化合物的有益作用部分是通过激活 PPARδ来介导的。这篇综述讨论了关于 PPARδ激活对 PGI₂和 PGI₂稳定类似物的血管保护和再生功能的贡献的新证据。